Efficacy comparison of duloxetine and SSRIs at doses approved in Japan

Código QR

Efficacy comparison of duloxetine and SSRIs at doses approved in Japan

Eiji Harada,1 Alexander Schacht,2 Tsukasa Koyama,3 Lauren Marangell,4,5 Toshinaga Tsuji,6 Rodrigo Escobar41Medical Science, Eli Lilly Japan K.K, Kobe, Japan; 2Global Statistical Sciences, Eli Lilly and Company, Bad Homburg, Germany; 3Clinical Research Center, Ohyachi Hospital, Sapporo, Japan; 4Eli...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Harada E, Schacht A, Koyama T, Marangell LB, Tsuji T, Escobar R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/4adbe709deab40f798a54210e471a1f8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Treatment discontinuation and tolerability as a function of dose and titration of duloxetine in the treatment of major depressive disorder
por: Harada E, et al.
Publicado: (2016)

Duloxetine in the treatment of generalized anxiety disorder
por: Trevor R Norman, et al.
Publicado: (2009)

The role of duloxetine in the treatment of anxiety disorders
por: Domenico De Berardis, et al.
Publicado: (2008)

Duloxetine in panic disorder with somatic gastric pain
por: Preve M, et al.
Publicado: (2013)

Duloxetine for the treatment of generalized anxiety disorder: a review
por: Ahsan Y Khan, et al.
Publicado: (2008)

New treatment options for fibromyalgia: critical appraisal of duloxetine
por: Nurcan &Uuml;&ccedil;eyler, et al.
Publicado: (2008)

Effect of depressive symptoms on the length of hospital stay among patients hospitalized for acute stroke in Japan
por: Sugawara N, et al.
Publicado: (2015)

Comparative clinical profile of mirtazapine and duloxetine in practical clinical settings in Japan: a 4-week open-label, parallel-group study of major depressive disorder
por: Nagao K, et al.
Publicado: (2013)

Impact of serotonin transporter gene on rTMS augmentation of SSRIs for obsessive compulsive disorder
por: Zhang K, et al.
Publicado: (2019)

Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis
por: Babij R, et al.
Publicado: (2015)

Comparison of duloxetine and SSRI as a treatment option of painful physical symptoms associated with major depressive disorder
por: Haider M, et al.
Publicado: (2017)

Association between pain severity, depression severity, and use of health care services in Japan: results of a nationwide survey
por: Vietri J, et al.
Publicado: (2015)

An observational study of duloxetine versus SSRI monotherapy for the treatment of painful physical symptoms in Japanese patients with major depressive disorder: primary analysis
por: Kuga A, et al.
Publicado: (2017)

Analysis of HAM-D scores and working ability in an observational study of Japanese patients with major depressive disorder and painful physical symptoms treated with duloxetine or SSRI monotherapy
por: Kuga A, et al.
Publicado: (2019)

Early symptom non-improvement and aggravation are associated with the treatment response to SSRIs in MDD: a real-world study
por: Yuan H, et al.
Publicado: (2019)

Maintaining efficacy in the treatment of diabetic peripheral neuropathic pain: role of duloxetine
por: Lindsay Zilliox, et al.
Publicado: (2010)

An observational study of duloxetine versus SSRI monotherapy in Japanese patients with major depressive disorder: subgroup analyses of treatment effectiveness for pain, depressive symptoms, and quality of life
por: Kuga A, et al.
Publicado: (2017)

Efficacy of low-dose D2/D3 partial agonist pramipexole on neuroleptic-induced extrapyramidal symptoms and symptoms of schizophrenia: a stage-1 open-label pilot study
por: Weng JJ, et al.
Publicado: (2019)

Maintaining efficacy in the treatment of diabetic peripheral neuropathic pain: role of duloxetine
por: Russell J, et al.
Publicado: (2010)

Efficacy and safety of intravenous nimodipine administration for treatment of hypertension in patients with intracerebral hemorrhage
por: Li YQ, et al.
Publicado: (2015)

Low-dose oral prolonged-release oxycodone/naloxone for chronic pain in elderly patients with cognitive impairment: an efficacy–tolerability pilot study
por: Petrò E, et al.
Publicado: (2016)

Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review
por: Maneeton B, et al.
Publicado: (2018)

Telomere length in blood cells is related to the chronicity, severity, and recurrence rate of schizophrenia
por: Pawelczyk T, et al.
Publicado: (2015)

Korean Medication Algorithm for Bipolar Disorder 2014: comparisons with other treatment guidelines
por: Jeong JH, et al.
Publicado: (2015)

Functioning in patients with major depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia
por: Novick D, et al.
Publicado: (2016)

Clinical outcomes of patients with major depressive disorder treated with either duloxetine, escitalopram, fluoxetine, paroxetine, or sertraline
por: Huang J, et al.
Publicado: (2018)

Catatonia in Down syndrome; a treatable cause of regression
por: Ghaziuddin N, et al.
Publicado: (2015)

Correlation between pain response and improvements in patient-reported outcomes and health-related quality of life in duloxetine-treated patients with diabetic peripheral neuropathic pain
por: Ogawa K, et al.
Publicado: (2015)

Long-term administration of escitalopram in patients with social anxiety disorder in Japan
por: Asakura S, et al.
Publicado: (2016)

Does early improvement in depressive symptoms predict subsequent remission in patients with depression who are treated with duloxetine?
por: Sueki A, et al.
Publicado: (2016)

Association of metabotropic glutamate receptor 3 gene polymorphisms with schizophrenia risk: evidence from a meta-analysis
por: Yang X, et al.
Publicado: (2015)

Comparison of three screening tests for autism in preterm children with birth weights less than 1,500 grams
por: Dudova I, et al.
Publicado: (2014)

Perceptions and impact of bipolar disorder in Japan: results of an Internet survey
por: Watanabe K, et al.
Publicado: (2016)

The cost of schizophrenia in Japan
por: Sado M, et al.
Publicado: (2013)

Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation
por: Michele Fornaro, et al.
Publicado: (2011)

Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial
por: Kang RY, et al.
Publicado: (2015)

Use of second-generation antipsychotics in the acute inpatient management of schizophrenia in the Middle East
por: Alkhadhari S, et al.
Publicado: (2015)

Defensive function of persecutory delusion and discrepancy between explicit and implicit self-esteem in schizophrenia: study using the Brief Implicit Association Test
por: Nakamura M, et al.
Publicado: (2014)

Shen-Qi-Jie-Yu-Fang has antidepressant effects in a rodent model of postpartum depression by regulating the immune organs and subsets of T lymphocytes
por: Qu M, et al.
Publicado: (2015)

Social cognitive and neurocognitive deficits in inpatients with unilateral thalamic lesions — pilot study
por: Wilkos E, et al.
Publicado: (2015)